- Home
- CYTK vs RDN Comparison
CYTK vs RDN Comparison
Compare CYTK & RDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- RDN
- Stock Information
- Founded
- CYTK 1997
- RDN 1977
- Country
- CYTK United States
- RDN United States
- Employees
- CYTK N/A
- RDN N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- RDN Property-Casualty Insurers
- Sector
- CYTK Health Care
- RDN Finance
- Exchange
- CYTK Nasdaq
- RDN Nasdaq
- Market Cap
- CYTK 5.6B
- RDN 4.6B
- IPO Year
- CYTK 2004
- RDN 1992
- Fundamental
- Price
- CYTK $32.00
- RDN $33.78
- Analyst Decision
- CYTK Buy
- RDN Buy
- Analyst Count
- CYTK 15
- RDN 6
- Target Price
- CYTK $73.71
- RDN $36.83
- AVG Volume (30 Days)
- CYTK 2.0M
- RDN 971.8K
- Earning Date
- CYTK 05-06-2025
- RDN 07-30-2025
- Dividend Yield
- CYTK N/A
- RDN 3.02%
- EPS Growth
- CYTK N/A
- RDN 4.01
- EPS
- CYTK N/A
- RDN 3.92
- Revenue
- CYTK $19,218,000.00
- RDN $1,288,979,000.00
- Revenue This Year
- CYTK $24.01
- RDN N/A
- Revenue Next Year
- CYTK $698.33
- RDN $2.74
- P/E Ratio
- CYTK N/A
- RDN $8.61
- Revenue Growth
- CYTK 412.21
- RDN 3.11
- 52 Week Low
- CYTK $29.31
- RDN $29.32
- 52 Week High
- CYTK $61.38
- RDN $37.86
- Technical
- Relative Strength Index (RSI)
- CYTK 44.20
- RDN 52.37
- Support Level
- CYTK $30.02
- RDN $33.78
- Resistance Level
- CYTK $31.27
- RDN $34.38
- Average True Range (ATR)
- CYTK 1.32
- RDN 0.64
- MACD
- CYTK 0.38
- RDN -0.08
- Stochastic Oscillator
- CYTK 72.12
- RDN 40.43
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one business segment Mortgage Insurance. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for the benefit of mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans, and also offers other credit risk management solutions, including contract underwriting, to customers. It also provides other mortgage and real estate products and services through Mortgage Conduit, Title, Real Estate Services, and Real Estate Technology businesses.